126 related articles for article (PubMed ID: 38229316)
1. Beneficial effect of 5-HT1b/1d agonist on Parkinson's disease by modulating glutamate and reducing deposition of α-synuclein.
Tripathi AS; Fatima N; Tripathi P; Tripathi R; Alka ; Zaki MEA; Mohapatra L; Yasir M; Maurya RK
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23627. PubMed ID: 38229316
[TBL] [Abstract][Full Text] [Related]
2. Activation of 5-HT 1b/d receptor restores the cognitive function by reducing glutamate release, deposition of β-amyloid and TLR-4 pathway in the brain of scopolamine-induced dementia in rat.
Tripathi AS; Bansod P; Swathi KP
J Pharm Pharmacol; 2021 Dec; 73(12):1592-1598. PubMed ID: 34244776
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Thomsen M; Stoica A; Christensen KV; Fryland T; Mikkelsen JD; Hansen JB
Exp Neurol; 2022 Dec; 358():114209. PubMed ID: 35988699
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evidence That 5-HT1B Receptor Agonists Show Promise as Medications for Psychostimulant Use Disorders.
Garcia R; Cotter AR; Leslie K; Olive MF; Neisewander JL
Int J Neuropsychopharmacol; 2017 Aug; 20(8):644-653. PubMed ID: 28444326
[TBL] [Abstract][Full Text] [Related]
5. Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
LeWitt PA; Stebbins GT; Christensen KV; Tan R; Pretorius A; Thomsen M
Mov Disord; 2024 Mar; 39(3):613-618. PubMed ID: 38314643
[TBL] [Abstract][Full Text] [Related]
6. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices.
Stepień A; Chalimoniuk M; Strosznajder J
Cephalalgia; 1999 Dec; 19(10):859-65. PubMed ID: 10668104
[TBL] [Abstract][Full Text] [Related]
7. N-methyl-D-aspartate receptor-mediated modulations of the anti-allodynic effects of 5-HT1B/1D receptor stimulation in a rat model of trigeminal neuropathic pain.
Kayser V; Latrémolière A; Hamon M; Bourgoin S
Eur J Pain; 2011 May; 15(5):451-8. PubMed ID: 20965753
[TBL] [Abstract][Full Text] [Related]
8. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
9. Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder.
Boshuisen ML; den Boer JA
Psychopharmacology (Berl); 2000 Sep; 152(1):74-9. PubMed ID: 11041318
[TBL] [Abstract][Full Text] [Related]
10. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
MacLennan SJ; Cambridge D; Whiting MV; Marston C; Martin GR
Eur J Pharmacol; 1998 Nov; 361(2-3):191-7. PubMed ID: 9865508
[TBL] [Abstract][Full Text] [Related]
11. Reduction of spinal sensory transmission by facilitation of 5-HT1B/D receptors in noninjured and spinal cord-injured humans.
D'Amico JM; Li Y; Bennett DJ; Gorassini MA
J Neurophysiol; 2013 Mar; 109(6):1485-93. PubMed ID: 23221401
[TBL] [Abstract][Full Text] [Related]
12. A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers.
Varnäs K; Jučaite A; McCarthy DJ; Stenkrona P; Nord M; Halldin C; Farde L; Kanes S
Cephalalgia; 2013 Jul; 33(10):853-60. PubMed ID: 23430984
[TBL] [Abstract][Full Text] [Related]
13. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats.
Cumberbatch MJ; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1998 Nov; 362(1):43-6. PubMed ID: 9865528
[TBL] [Abstract][Full Text] [Related]
14. Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in intestinal ischemia/reperfusion in rats.
Gharishvandi F; Abdollahi A; Shafaroodi H; Mohammad Jafari R; Pasalar P; Dehpour AR
Eur J Pharmacol; 2020 Sep; 882():173265. PubMed ID: 32574671
[TBL] [Abstract][Full Text] [Related]
15. Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice.
de Almeida RM; Nikulina EM; Faccidomo S; Fish EW; Miczek KA
Psychopharmacology (Berl); 2001 Sep; 157(2):131-41. PubMed ID: 11594437
[TBL] [Abstract][Full Text] [Related]
16. Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson's Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression.
Leão AH; Meurer YS; da Silva AF; Medeiros AM; Campêlo CL; Abílio VC; Engelberth RC; Cavalcante JS; Izídio GS; Ribeiro AM; Silva RH
Front Aging Neurosci; 2017; 9():78. PubMed ID: 28396635
[TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.
Kumar V; Singh D; Singh BK; Singh S; Mittra N; Jha RR; Patel DK; Singh C
Mol Cell Biochem; 2018 Jul; 444(1-2):149-160. PubMed ID: 29198021
[TBL] [Abstract][Full Text] [Related]
18. Preclinical support for the therapeutic potential of zolmitriptan as a treatment for cocaine use disorders.
Garcia R; Le T; Scott SN; Charmchi D; Sprout JML; Pentkowski NS; Neisewander JL
Transl Psychiatry; 2020 Aug; 10(1):266. PubMed ID: 32747623
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques.
Nilsson T; Longmore J; Shaw D; Pantev E; Bard JA; Branchek T; Edvinsson L
Eur J Pharmacol; 1999 May; 372(1):49-56. PubMed ID: 10374714
[TBL] [Abstract][Full Text] [Related]
20. Exercise attenuates neuronal degeneration in Parkinson's disease rat model by regulating the level of adenosine 2A receptor.
Li R; Jin S; He J; Peng Y; Wei L; Gu L
Folia Neuropathol; 2023; 61(2):217-223. PubMed ID: 37587896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
